CELL HOST MICROBE:疟原虫入侵红细胞新机制 潜在药物靶点

2017-06-15 海北 MedSci原创

细胞内寄生虫必须侵入宿主细胞才能成熟并且进行传播。疟原虫就是一种细胞内寄生虫,其必须侵袭宿主红细胞才能完成生命周期。 昨天 Manuel Llinás课题组在细胞宿主和微生物(Cell Host & Microbe)杂志发文,阐述疟原虫侵袭宿主红细胞新机制。他们发现属于Apicomplexan AP2(ApiAP2)家族的寄生虫特异性转录因子PfAP2-I可以负责调控疟原虫与宿主红细

细胞内寄生虫必须侵入宿主细胞才能成熟并且进行传播。疟原虫就是一种细胞内寄生虫,其必须侵袭宿主红细胞才能完成生命周期。

昨天 Manuel Llinás课题组在细胞宿主和微生物(Cell Host & Microbe)杂志发文,阐述疟原虫侵袭宿主红细胞新机制。他们发现属于Apicomplexan AP2ApiAP2)家族的寄生虫特异性转录因子PfAP2-I可以负责调控疟原虫与宿主红细胞侵袭相关的基因表达。科学家们利用ChIP-seq进行全基因组分析,发现PfAP2-1可以与靶基因启动子中的特定DNA序列相互作用。虽然PfAP2-I一共含有三个AP2 DNA结合结构域,但是在血液发育阶段,只有一个是和靶基因结合必须的。

此外,科学家们发现PfAP2-1还能够和疟原虫染色质相关蛋白关联,包括疟原虫溴结构域蛋白PfBDP1。两者形成的复合物和基因表达调控相关。

疟原虫的宿主红细胞侵袭涉及疟原虫和宿主表面蛋白的相互租用。入侵过程很快,介导疟原虫结合宿主的蛋白质具有冗余性。此外,由于循环中的裂殖子表面蛋白变体较多,所以难以设计疫苗。PfAP2-I作为一个宿主红细胞入侵的关键调节因子,代表了一种潜在的新型抗疟药物靶点。

原始出处:

Joana Mendonca Santos et al. Red Blood Cell Invasion by the Malaria Parasite Is Coordinated by the PfAP2-I Transcription Factor.  2017, Cell Host & Microbe 21, 731–741. DOI: http://dx.doi.org/10.1016/j.chom.2017.05.006

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1870007, encodeId=66f718e00071f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 24 10:36:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084232, encodeId=b4832084232e8, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 29 09:36:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923694, encodeId=6dca1923694c1, content=<a href='/topic/show?id=bf0a66e12f4' target=_blank style='color:#2F92EE;'>#潜在药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66712, encryptionId=bf0a66e12f4, topicName=潜在药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Mon Mar 12 01:36:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857466, encodeId=75b9185e46611, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Fri Oct 20 23:36:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960266, encodeId=6326196026627, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 13 16:36:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281958, encodeId=faca1281958e2, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384937, encodeId=7863138493ed5, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387846, encodeId=a8f1138e84633, content=<a href='/topic/show?id=25ffe04313d' target=_blank style='color:#2F92EE;'>#疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70431, encryptionId=25ffe04313d, topicName=疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1870007, encodeId=66f718e00071f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 24 10:36:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084232, encodeId=b4832084232e8, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 29 09:36:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923694, encodeId=6dca1923694c1, content=<a href='/topic/show?id=bf0a66e12f4' target=_blank style='color:#2F92EE;'>#潜在药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66712, encryptionId=bf0a66e12f4, topicName=潜在药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Mon Mar 12 01:36:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857466, encodeId=75b9185e46611, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Fri Oct 20 23:36:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960266, encodeId=6326196026627, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 13 16:36:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281958, encodeId=faca1281958e2, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384937, encodeId=7863138493ed5, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387846, encodeId=a8f1138e84633, content=<a href='/topic/show?id=25ffe04313d' target=_blank style='color:#2F92EE;'>#疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70431, encryptionId=25ffe04313d, topicName=疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2018-05-29 xjy02
  3. [GetPortalCommentsPageByObjectIdResponse(id=1870007, encodeId=66f718e00071f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 24 10:36:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084232, encodeId=b4832084232e8, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 29 09:36:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923694, encodeId=6dca1923694c1, content=<a href='/topic/show?id=bf0a66e12f4' target=_blank style='color:#2F92EE;'>#潜在药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66712, encryptionId=bf0a66e12f4, topicName=潜在药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Mon Mar 12 01:36:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857466, encodeId=75b9185e46611, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Fri Oct 20 23:36:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960266, encodeId=6326196026627, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 13 16:36:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281958, encodeId=faca1281958e2, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384937, encodeId=7863138493ed5, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387846, encodeId=a8f1138e84633, content=<a href='/topic/show?id=25ffe04313d' target=_blank style='color:#2F92EE;'>#疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70431, encryptionId=25ffe04313d, topicName=疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1870007, encodeId=66f718e00071f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 24 10:36:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084232, encodeId=b4832084232e8, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 29 09:36:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923694, encodeId=6dca1923694c1, content=<a href='/topic/show?id=bf0a66e12f4' target=_blank style='color:#2F92EE;'>#潜在药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66712, encryptionId=bf0a66e12f4, topicName=潜在药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Mon Mar 12 01:36:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857466, encodeId=75b9185e46611, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Fri Oct 20 23:36:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960266, encodeId=6326196026627, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 13 16:36:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281958, encodeId=faca1281958e2, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384937, encodeId=7863138493ed5, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387846, encodeId=a8f1138e84633, content=<a href='/topic/show?id=25ffe04313d' target=_blank style='color:#2F92EE;'>#疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70431, encryptionId=25ffe04313d, topicName=疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1870007, encodeId=66f718e00071f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 24 10:36:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084232, encodeId=b4832084232e8, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 29 09:36:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923694, encodeId=6dca1923694c1, content=<a href='/topic/show?id=bf0a66e12f4' target=_blank style='color:#2F92EE;'>#潜在药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66712, encryptionId=bf0a66e12f4, topicName=潜在药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Mon Mar 12 01:36:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857466, encodeId=75b9185e46611, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Fri Oct 20 23:36:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960266, encodeId=6326196026627, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 13 16:36:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281958, encodeId=faca1281958e2, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384937, encodeId=7863138493ed5, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387846, encodeId=a8f1138e84633, content=<a href='/topic/show?id=25ffe04313d' target=_blank style='color:#2F92EE;'>#疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70431, encryptionId=25ffe04313d, topicName=疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2018-05-13 维他命
  6. [GetPortalCommentsPageByObjectIdResponse(id=1870007, encodeId=66f718e00071f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 24 10:36:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084232, encodeId=b4832084232e8, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 29 09:36:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923694, encodeId=6dca1923694c1, content=<a href='/topic/show?id=bf0a66e12f4' target=_blank style='color:#2F92EE;'>#潜在药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66712, encryptionId=bf0a66e12f4, topicName=潜在药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Mon Mar 12 01:36:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857466, encodeId=75b9185e46611, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Fri Oct 20 23:36:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960266, encodeId=6326196026627, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 13 16:36:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281958, encodeId=faca1281958e2, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384937, encodeId=7863138493ed5, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387846, encodeId=a8f1138e84633, content=<a href='/topic/show?id=25ffe04313d' target=_blank style='color:#2F92EE;'>#疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70431, encryptionId=25ffe04313d, topicName=疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1870007, encodeId=66f718e00071f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 24 10:36:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084232, encodeId=b4832084232e8, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 29 09:36:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923694, encodeId=6dca1923694c1, content=<a href='/topic/show?id=bf0a66e12f4' target=_blank style='color:#2F92EE;'>#潜在药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66712, encryptionId=bf0a66e12f4, topicName=潜在药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Mon Mar 12 01:36:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857466, encodeId=75b9185e46611, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Fri Oct 20 23:36:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960266, encodeId=6326196026627, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 13 16:36:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281958, encodeId=faca1281958e2, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384937, encodeId=7863138493ed5, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387846, encodeId=a8f1138e84633, content=<a href='/topic/show?id=25ffe04313d' target=_blank style='color:#2F92EE;'>#疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70431, encryptionId=25ffe04313d, topicName=疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-06-17 xugc
  8. [GetPortalCommentsPageByObjectIdResponse(id=1870007, encodeId=66f718e00071f, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Sep 24 10:36:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084232, encodeId=b4832084232e8, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Tue May 29 09:36:00 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923694, encodeId=6dca1923694c1, content=<a href='/topic/show?id=bf0a66e12f4' target=_blank style='color:#2F92EE;'>#潜在药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66712, encryptionId=bf0a66e12f4, topicName=潜在药物)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLc3PoqaNe4QTZ947pojXuchvvmkkJN0wyBBbA3LVX2WDkgiaJ7cswu9yvA4CB0NicjcrCfBY1zRPkA/132, createdBy=b3812500089, createdName=ms6897892027066920, createdTime=Mon Mar 12 01:36:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857466, encodeId=75b9185e46611, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Fri Oct 20 23:36:00 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960266, encodeId=6326196026627, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun May 13 16:36:00 CST 2018, time=2018-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281958, encodeId=faca1281958e2, content=<a href='/topic/show?id=3dece71531e' target=_blank style='color:#2F92EE;'>#红细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77153, encryptionId=3dece71531e, topicName=红细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384937, encodeId=7863138493ed5, content=<a href='/topic/show?id=93618e90631' target=_blank style='color:#2F92EE;'>#药物靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87906, encryptionId=93618e90631, topicName=药物靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e1c493, createdName=xugc, createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387846, encodeId=a8f1138e84633, content=<a href='/topic/show?id=25ffe04313d' target=_blank style='color:#2F92EE;'>#疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70431, encryptionId=25ffe04313d, topicName=疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Sat Jun 17 12:36:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]

相关资讯

PLON ONE:使用微滴数字PCR 对四种人疟原虫进行定量检测

微滴数字聚合酶链反应(ddPCR)是基于水-油乳液微滴技术的微滴技术。它是一种用于检测和描绘复杂背景的次要等位基因的高灵敏度方法,并且能够提供靶标DNA的绝对定量。ddPCR技术已经被应用于多种病原体的检测。

4月25日世界防治疟疾日 盘点疟疾研究重大进展

疟疾是经按蚊叮咬或输入带疟原虫者的血液而感染疟原虫所引起的虫媒传染病。寄生于人体的疟原虫共有五种,即间日疟原虫,三日疟原虫,恶性疟原虫、卵形疟原虫和诺氏疟原虫。一旦疟原虫通过蚊子叮咬进入人体,它们先在肝脏中增殖,随后侵入红细胞,在那里,它们导致所有的疟疾症状。疟疾能通过受感染的蚊虫叮咬传播,影响了世界上97个国家和地区。

疟原虫体内的神奇蛋白竟可对抗100多种癌细胞

疟原虫也能治癌症了?前几天, 知名杂志European Urology上刊登了一篇文章,研究人员从疟原虫体内分离出一种称为VAR2CSA的蛋白质,通过对VAR2SCA进行结构改造添加细胞毒性药物,研究人员发现,这种疟疾蛋白质药物组合显著延长了对顺铂化疗完全耐药的高度侵袭性膀胱癌小鼠的生存期。

NEJM:新一代抗疟药物KAF156显示出较好的抗疟活性和安全性

KAF156是一种新型的抗疟药物类(imidazolopiperazines),在疟原虫蔓延至血液之前或之中,以及红前期肝阶段都具有活性。研究人员在泰国和越南的5个中心进行了一项2期、开放式标签研究来评估成人急性间日疟原虫和恶性疟原虫感染使用抗疟药物KAF156的疗效及安全性。评估患者经抗疟治疗后的寄生虫清除率,间日疟原虫或恶性疟原虫感染的患者给予多剂量抗疟药治疗(400毫克/日,3天),接着评估

2017年3月10日Science期刊精华

本周又有一期新的Science期刊(2017年3月10日)发布,它有哪些精彩研究呢?让小编一一道来。 1.Science特刊:7篇长文解读人工合成酵母染色体——开启合成生命新纪元! doi:10.1126/science.aaf4597 doi:10.1126/science.aaf4831 doi:10.1126/science.aaf4

Oncotarget:科学家揭示疟原虫抗肝脏肿瘤免疫机制

日前,中科院广州生物医药与健康研究院陈小平课题组首次揭示了疟原虫作为肿瘤抗原表达载体及其抗肝脏肿瘤(HCC)的免疫机制,这为疟原虫用于肿瘤免疫治疗提供了有力的临床前数据支持。相关研究成果已在线发表在《癌靶标》。